Detailed information for compound 592230
Basic information
Technical information
- TDR Targets ID: 592230
- Name: 8,9-dimethoxy-N-(oxolan-2-ylmethyl)-2-phenyl- [1,2,4]triazolo[1,5-c]quinazolin-5-amine
- MW: 405.45 | Formula: C22H23N5O3
-
H donors: 1
H acceptors: 3
LogP: 3.76
Rotable bonds: 6
Rule of 5 violations (Lipinski): 1 - SMILES: COc1cc2c(cc1OC)nc(n1c2nc(n1)c1ccccc1)NCC1CCCO1
- InChi: 1S/C22H23N5O3/c1-28-18-11-16-17(12-19(18)29-2)24-22(23-13-15-9-6-10-30-15)27-21(16)25-20(26-27)14-7-4-3-5-8-14/h3-5,7-8,11-12,15H,6,9-10,13H2,1-2H3,(H,23,24)
- InChiKey: CBGFXGBHHASUCY-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- 8,9-dimethoxy-2-phenyl-N-(tetrahydrofuran-2-ylmethyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine
- 8,9-dimethoxy-2-phenyl-N-(2-tetrahydrofuranylmethyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine
- (8,9-dimethoxy-2-phenyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)-(tetrahydrofurfuryl)amine
Targets
Known targets for this compound
No curated genes were found associated with this compound
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Echinococcus granulosus | CREB binding protein | 0.012132 | 0 | 0.5 |
| Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0154836 | 1 | 0.5 |
| Echinococcus granulosus | CREB binding protein | 0.012132 | 0 | 0.5 |
| Plasmodium falciparum | lysophospholipase, putative | 0.0154836 | 1 | 0.5 |
| Trypanosoma brucei | monoglyceride lipase, putative | 0.0154836 | 1 | 0.5 |
| Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0154836 | 1 | 0.5 |
| Trypanosoma cruzi | monoglyceride lipase, putative | 0.0154836 | 1 | 0.5 |
| Plasmodium vivax | PST-A protein | 0.0154836 | 1 | 0.5 |
| Plasmodium falciparum | esterase, putative | 0.0154836 | 1 | 0.5 |
| Mycobacterium ulcerans | hypothetical protein | 0.0154836 | 1 | 0.5 |
| Trypanosoma brucei | monoglyceride lipase, putative | 0.0154836 | 1 | 0.5 |
| Brugia malayi | TAZ zinc finger family protein | 0.012132 | 0 | 0.5 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0154836 | 1 | 0.5 |
| Leishmania major | monoglyceride lipase, putative | 0.0154836 | 1 | 0.5 |
| Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0154836 | 1 | 0.5 |
| Entamoeba histolytica | hydrolase, alpha/beta fold family domain containing protein | 0.0154836 | 1 | 0.5 |
| Schistosoma mansoni | CREB-binding protein 1 (SmCBP1) | 0.012132 | 0 | 0.5 |
| Mycobacterium ulcerans | lysophospholipase | 0.0154836 | 1 | 0.5 |
| Loa Loa (eye worm) | CBP-B | 0.012132 | 0 | 0.5 |
| Trichomonas vaginalis | conserved hypothetical protein | 0.0154836 | 1 | 0.5 |
| Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0154836 | 1 | 0.5 |
| Mycobacterium leprae | POSSIBLE LYSOPHOSPHOLIPASE | 0.0154836 | 1 | 0.5 |
| Trichomonas vaginalis | Clan SC, family S33, methylesterase-like serine peptidase | 0.0154836 | 1 | 0.5 |
| Echinococcus multilocularis | CREB binding protein | 0.012132 | 0 | 0.5 |
| Plasmodium falciparum | lysophospholipase, putative | 0.0154836 | 1 | 0.5 |
| Schistosoma mansoni | CREB-binding protein 2 | 0.012132 | 0 | 0.5 |
| Trichomonas vaginalis | valacyclovir hydrolase, putative | 0.0154836 | 1 | 0.5 |
| Entamoeba histolytica | hydrolase, alpha/beta fold family domain containing protein | 0.0154836 | 1 | 0.5 |
| Plasmodium falciparum | lysophospholipase, putative | 0.0154836 | 1 | 0.5 |
| Mycobacterium tuberculosis | Possible lysophospholipase | 0.0154836 | 1 | 0.5 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| Activity (functional) | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | ChEMBL. | 22096101 | |
| CC50 (functional) | > 100 uM | Huh7 cytotoxicity for Pf inhibitors | Novartis-GNF Malaria Box. | No reference |
| CC50 | > 100 uM | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | ChEMBL. | 18579783 |
| EC50 (functional) | = 0.2932 uM | PF proliferation inhibition 3D7 | Novartis-GNF Malaria Box. | No reference |
| EC50 (functional) | = 0.2932 uM | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
| EC50 (functional) | = 0.662 uM | W2 Pf proliferation inhibition | Novartis-GNF Malaria Box. | No reference |
| EC50 (functional) | = 0.662 uM | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | ChEMBL. | 18579783 |
| IFI promiscuity index | = 0.02273 | IFI promiscuity index | Novartis-GNF Malaria Box. | No reference |
| Inhibition (functional) | = 0 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
| Inhibition (functional) | = 0 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
| Inhibition (functional) | = 2.53 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
| Inhibition (functional) | = 6.19 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
| Inhibition (functional) | = 8.44 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
| Inhibition (functional) | = 92 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
| Inhibition (functional) | = 97 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
| Inhibition frequency index (IFI) (functional) | = 0 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
| Percent growth inhibition (functional) | = -9 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
| Percent growth inhibition (functional) | = -7 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
| Percent growth inhibition (functional) | = 92 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
| Percent growth inhibition (functional) | = 97 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
| XC50 (functional) | = 6.68 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
| XC50 (functional) | = 0.2107 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Plasmodium falciparum | ChEMBL23 | 18579783 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL527838
- Search by GSK
- Search by Novartis-GNF Malaria Box
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.